TWI923545B - 19-去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 - Google Patents
19-去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法Info
- Publication number
- TWI923545B TWI923545B TW108120367A TW108120367A TWI923545B TW I923545 B TWI923545 B TW I923545B TW 108120367 A TW108120367 A TW 108120367A TW 108120367 A TW108120367 A TW 108120367A TW I923545 B TWI923545 B TW I923545B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- individual
- approximately
- weeks
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684155P | 2018-06-12 | 2018-06-12 | |
| US62/684,155 | 2018-06-12 | ||
| US201962789329P | 2019-01-07 | 2019-01-07 | |
| US62/789,329 | 2019-01-07 | ||
| US201962841645P | 2019-05-01 | 2019-05-01 | |
| US62/841,645 | 2019-05-01 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202005653A TW202005653A (zh) | 2020-02-01 |
| TWI923545B true TWI923545B (zh) | 2026-05-01 |
Family
ID=67211854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108120367A TWI923545B (zh) | 2018-06-12 | 2019-06-12 | 19-去甲c3,3-二取代之c21-n-吡唑類固醇及其使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20210338692A1 (enExample) |
| EP (1) | EP3806863A1 (enExample) |
| JP (3) | JP2021527092A (enExample) |
| KR (1) | KR20210021005A (enExample) |
| CN (2) | CN117959309A (enExample) |
| AU (2) | AU2019287491B2 (enExample) |
| CA (1) | CA3103421A1 (enExample) |
| IL (1) | IL279315A (enExample) |
| MA (1) | MA52894A (enExample) |
| MX (2) | MX2020013557A (enExample) |
| SG (1) | SG11202012344RA (enExample) |
| TW (1) | TWI923545B (enExample) |
| WO (1) | WO2019241442A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201606063RA (en) | 2012-01-23 | 2016-09-29 | Sage Therapeutics Inc | Neuroactive steroid formulations and methods of treating cns disorders |
| RS62761B1 (sr) | 2012-08-21 | 2022-01-31 | Sage Therapeutics Inc | Alopregnanolon za lečenje refraktornog epileptičkog statusa |
| SMT202100509T1 (it) | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| WO2016082789A1 (en) | 2014-11-27 | 2016-06-02 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2018013613A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| TW202604538A (zh) | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| US20230018765A1 (en) * | 2019-12-05 | 2023-01-19 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| CN115551514A (zh) | 2020-03-25 | 2022-12-30 | 萨奇治疗股份有限公司 | 用于治疗呼吸系统病症的药物的用途 |
| CA3187178A1 (en) * | 2020-07-20 | 2022-01-27 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| WO2022165017A1 (en) * | 2021-01-28 | 2022-08-04 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| JP2024510436A (ja) * | 2021-03-17 | 2024-03-07 | セージ セラピューティクス， インコーポレイテッド | 大うつ病性障害の処置のための１９－ノルｃ３，３－２置換ｃ２１－ｎ－ピラゾリルステロイド |
| MX2023012728A (es) * | 2021-04-29 | 2023-11-08 | Sage Therapeutics Inc | Esteroide neuroactivo para el tratamiento del trastorno depresivo mayor y la depresion posparto en una mujer lactante. |
| MX2023012727A (es) * | 2021-04-29 | 2023-11-08 | Sage Therapeutics Inc | Esteroide c21 -n-pirazolilo disubstituido 19-nor c3,3 para uso en el tratamiento de principales trastorno depresivo y depresion posparto. |
| JP2025508406A (ja) * | 2022-02-16 | 2025-03-26 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ関連障害を処置するための神経活性ステロイド |
| WO2025175214A1 (en) * | 2024-02-16 | 2025-08-21 | Engrail Therapeutics, Inc. | Methods of treating generalized anxiety disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202100509T1 (it) * | 2013-04-17 | 2021-11-12 | Sage Therapeutics Inc | Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia |
| JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| US20170233433A1 (en) * | 2014-10-16 | 2017-08-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| PH12018501923B1 (en) * | 2016-03-08 | 2024-06-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| TW202604538A (zh) * | 2016-08-23 | 2026-02-01 | 美商賽吉醫療公司 | 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇 |
| EP3678670A1 (en) * | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
-
2019
- 2019-06-12 WO PCT/US2019/036848 patent/WO2019241442A1/en not_active Ceased
- 2019-06-12 CA CA3103421A patent/CA3103421A1/en active Pending
- 2019-06-12 MA MA052894A patent/MA52894A/fr unknown
- 2019-06-12 MX MX2020013557A patent/MX2020013557A/es unknown
- 2019-06-12 CN CN202410051762.8A patent/CN117959309A/zh active Pending
- 2019-06-12 SG SG11202012344RA patent/SG11202012344RA/en unknown
- 2019-06-12 US US17/251,475 patent/US20210338692A1/en active Pending
- 2019-06-12 JP JP2020569024A patent/JP2021527092A/ja active Pending
- 2019-06-12 EP EP19737327.7A patent/EP3806863A1/en active Pending
- 2019-06-12 CN CN201980051843.5A patent/CN112533611A/zh active Pending
- 2019-06-12 KR KR1020217000726A patent/KR20210021005A/ko active Pending
- 2019-06-12 AU AU2019287491A patent/AU2019287491B2/en active Active
- 2019-06-12 TW TW108120367A patent/TWI923545B/zh active
- 2019-12-05 US US16/704,800 patent/US20200113917A1/en not_active Abandoned
-
2020
- 2020-12-09 IL IL279315A patent/IL279315A/en unknown
- 2020-12-11 MX MX2025000166A patent/MX2025000166A/es unknown
-
2022
- 2022-06-17 US US17/843,031 patent/US20220323462A1/en not_active Abandoned
-
2023
- 2023-12-05 JP JP2023205211A patent/JP2024028849A/ja active Pending
-
2024
- 2024-12-12 US US18/978,431 patent/US20250339447A1/en active Pending
-
2025
- 2025-04-10 JP JP2025064902A patent/JP2025108553A/ja active Pending
- 2025-08-15 AU AU2025217363A patent/AU2025217363A1/en active Pending
Non-Patent Citations (1)
| Title |
|---|
| 期刊 Gabriel Martinez Botella "Neuroactive Steroids. 2. 3α-Hydroxy-3β-methyl-21-(4- cyano‑1H‑pyrazol-1′-yl)-19-nor-5β-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (γ-Aminobutyric Acid)A Receptor" J. Med. Chem. 2017, 60, 20170817 7810−7819 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20200113917A1 (en) | 2020-04-16 |
| AU2019287491B2 (en) | 2025-05-15 |
| CN112533611A (zh) | 2021-03-19 |
| US20210338692A1 (en) | 2021-11-04 |
| JP2025108553A (ja) | 2025-07-23 |
| MX2020013557A (es) | 2021-05-27 |
| TW202005653A (zh) | 2020-02-01 |
| SG11202012344RA (en) | 2021-01-28 |
| US20220323462A1 (en) | 2022-10-13 |
| EP3806863A1 (en) | 2021-04-21 |
| JP2021527092A (ja) | 2021-10-11 |
| MA52894A (fr) | 2021-04-21 |
| AU2025217363A1 (en) | 2025-09-04 |
| CA3103421A1 (en) | 2019-12-19 |
| US20250339447A1 (en) | 2025-11-06 |
| MX2025000166A (es) | 2025-03-07 |
| CN117959309A (zh) | 2024-05-03 |
| KR20210021005A (ko) | 2021-02-24 |
| JP2024028849A (ja) | 2024-03-05 |
| AU2019287491A1 (en) | 2021-01-07 |
| WO2019241442A1 (en) | 2019-12-19 |
| IL279315A (en) | 2021-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250339447A1 (en) | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| US20240216395A1 (en) | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression | |
| TW202133863A (zh) | １９—ｎｏｒ—ｃ３，３—二取代—ｃ２１—ｎ—吡唑基類固醇及使用其之方法 | |
| US20250295674A1 (en) | Neuroactive steroids for treatment of cns-related disorders | |
| Shaddy et al. | The pediatric randomized carvedilol trial in children with chronic heart failure: rationale and design | |
| TW202019425A (zh) | 利用經取代胺基-嘧啶化合物治療及預防多發性硬化症之方法 | |
| Li et al. | Comparison of acupuncture pretreatment followed by letrozole versus letrozole alone on live birth in anovulatory infertile women with polycystic ovary syndrome: a study protocol for a randomised controlled trial | |
| RU2851101C2 (ru) | 19-nor с3,3-замещенный с21-n-пиразолилстероид и способы его применения | |
| Horlen et al. | Side effects of antihistamines (H1 receptor antagonists) | |
| US20240238290A1 (en) | Use of complement factor d inhibitor for treatment of generalized myasthenia gravis | |
| Network et al. | MTN-042 | |
| WO2025257799A1 (en) | Methods of treating dravet syndrome | |
| CN120981229A (zh) | 用于治疗先天性肾上腺皮质增生症的组合物和方法 | |
| CN117580581A (zh) | 用于治疗重度抑郁障碍和产后抑郁症的19-去甲c3,3-二取代的c21-n-吡唑基类固醇 | |
| EA044015B1 (ru) | Дейтетрабеназин для лечения дискинезии при церебральном параличе | |
| Ferreira | 1.5 CEUs | |
| Smith et al. | A collaborative approach to myasthenia gravis: this chronic autoimmune disorder is caused by antibodies that block muscle cells from receiving neurotransmitters from the nerve cell | |
| Tebas | CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION | |
| Global | new approaches to hiv prevention |